| 000 | 01729naaaa2200301uu 4500 | ||
|---|---|---|---|
| 001 | https://directory.doabooks.org/handle/20.500.12854/65463 | ||
| 005 | 20220220043430.0 | ||
| 020 | _a1243 | ||
| 020 | _a9789533078212 | ||
| 020 | _a9789535167020 | ||
| 024 | 7 |
_a10.5772/1243 _cdoi |
|
| 041 | 0 | _aEnglish | |
| 042 | _adc | ||
| 072 | 7 |
_aMJCM _2bicssc |
|
| 100 | 1 |
_aPruitt, Joseph A. _4edt |
|
| 700 | 1 |
_aPruitt, Joseph A. _4oth |
|
| 245 | 1 | 0 | _aA Look into Myasthenia Gravis |
| 260 |
_bIntechOpen _c2012 |
||
| 300 | _a1 electronic resource (116 p.) | ||
| 506 | 0 |
_aOpen Access _2star _fUnrestricted online access |
|
| 520 | _aMyasthenia gravis is presently an incurable antibody-mediated autoimmune disorder characterized by generalized voluntary skeletal muscle weakness. The cause of the weakness is a defect at the neuromuscular junction level, in which autoimmune antibodies block the receptors responsible for initiating muscular contraction. Literally translated from its Latin and Greek etymological roots, myasthenia gravis means "grave muscle weakness". Fortunately, advances in modern medicine have resulted in a reduction of the truly "grave" outcomes for those inflicted but, without a cure, the gravity surrounding the disease remains | ||
| 540 |
_aCreative Commons _fhttps://creativecommons.org/licenses/by/3.0/ _2cc _4https://creativecommons.org/licenses/by/3.0/ |
||
| 546 | _aEnglish | ||
| 650 | 7 |
_aImmunology _2bicssc |
|
| 653 | _aImmunology | ||
| 856 | 4 | 0 |
_awww.oapen.org _uhttps://mts.intechopen.com/storage/books/735/authors_book/authors_book.pdf _70 _zDOAB: download the publication |
| 856 | 4 | 0 |
_awww.oapen.org _uhttps://directory.doabooks.org/handle/20.500.12854/65463 _70 _zDOAB: description of the publication |
| 999 |
_c65372 _d65372 |
||